MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.
MedChemexpress(MCE)provides a wide range of research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs and Natural compounds for laboratory and scientific use. MCE has an enthusiastic, energetic and friendly Technical and Customer Support team with years of experience in the Life Science industry. MCE lay great attention on the purity, stability and activity of the compounds, esp. You can rely on us to be a com...
View more >>
United States![CAS No:1037792-44-1 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-4-[[4-(tetrazol-1-yl)<br />phenoxy]methyl]-1,3-thiazole](/structure/cas-103/1037792-44-1.png)